The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
about
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experienceThe many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testingClonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.The significance of FOXP1 in diffuse large B-cell lymphoma.MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.New developments in the management of Waldenström macroglobulinemiaDiagnosis and management of neuropathies associated with plasma cell dyscrasias.Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization.The intricate role of CXCR4 in cancer.Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström's MacroglobulinemiaThe genetics of nodal marginal zone lymphomaTransgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia.Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations.MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.Ibrutinib for the treatment of Waldenström macroglobulinemia.Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.Waldenström Macroglobulinemia: Review of Pathogenesis and Management.Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.WHIM Syndrome Caused by Waldenström's Macroglobulinemia-Associated Mutation CXCR4 (L329fs).Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling.From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.
P2860
Q26738946-8E95BC60-C376-42CB-BB96-0461B9358678Q26784600-980805DE-25B5-4777-875F-F51DD1567DFFQ33617237-2EF93BA3-B33B-4DD9-85E2-116319A14538Q33869257-806F5DB2-4CA9-4123-A346-2D324259F9A5Q34047455-5D3B3619-B37E-4174-A074-753219212D00Q34435295-33E9C277-07C1-46E8-8622-68A5B514E46FQ34542980-BD9BC342-1AD6-48C2-AA97-60D4C607FA9FQ34553880-6782B8ED-23D2-463D-BAA7-677AE7C5671EQ34555067-C11F2FBA-CCAF-4508-8FA5-3A5C81B9B6EFQ34803768-50034452-1B05-4F7D-AAA1-C4E997EF1C14Q35067624-97BAFA74-BC9C-4EE1-9149-2FCC8F1BD5B6Q36533710-52911B09-1230-43BC-9C7C-280FAE719300Q36965870-19D75024-495D-40EF-BC80-539BFA191B09Q37237726-884AA7C8-1328-417B-B7D2-E43BE0200555Q37243257-CC063218-A3DC-4C2B-9CB3-0EC41D4AF218Q37490002-326D1671-F151-40FB-B031-A6812A0D1B7CQ37499211-DD2F7AB7-9194-4679-A4D8-4191DE209374Q37711782-BDAF0717-124B-4ACE-B5BD-CD3FF7815837Q38191449-9BE73447-A6C9-4D40-A2AA-97B8FF3AEA4DQ38413580-756FBDEA-B8B5-4B54-9E9B-A35612CEBAF3Q38542260-F0A37AE2-594F-4DFB-947A-F8666C496781Q38551391-D2F41AC6-A59D-4845-B011-109E22F1DE1CQ38635212-FA36F975-2AC7-49EF-AE2F-6C6EEE64876EQ38663689-198D98FA-23FA-44D8-8BAA-B8D121FD23C1Q38665207-4DAA37DA-4E29-4E0D-ABE9-2C7EEB3A9592Q38728585-8B022E4F-0114-451D-9F94-F88861097CF9Q38747789-37B33A07-2853-49EB-8135-98FFF7EEBF21Q38760522-08783132-45C4-40B5-BF4B-1F766D9D23E6Q38774535-3912BAE5-18BE-4448-AD3F-854585BFDD96Q38819164-94D60684-6514-4546-8B41-9D6A39E6286EQ38970612-6799969B-791F-4C6A-87B3-DE6A5F4EDBABQ39214071-85BEDD7E-851C-4DAE-9CE8-A2E28B761E1EQ39325783-B06771CF-D84A-4063-B29D-D31B31261728Q39375290-05974CF2-5D83-4047-88C9-59A47A8A514BQ39406673-B6D19F68-5F98-4CC7-9E2F-A1CB33C23EBBQ40722797-BB288ED7-32F2-4F0D-B427-1E134450A3E7Q40858735-773EFBB9-0953-49D6-892B-4E6719AF621FQ41070355-D196C564-3482-4E72-ADDE-05FEDDB7E0F2Q41081977-1E5B97C7-C1C7-46D9-A76D-1B511D3FC1C4Q41177165-732BBAA0-65C1-41BB-BC7F-17CC061B1E5E
P2860
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The genomic landscape of Walde ...... ed with B-cell lymphomagenesis
@ast
The genomic landscape of Walde ...... ed with B-cell lymphomagenesis
@en
The genomic landscape of Walde ...... ed with B-cell lymphomagenesis
@nl
type
label
The genomic landscape of Walde ...... ed with B-cell lymphomagenesis
@ast
The genomic landscape of Walde ...... ed with B-cell lymphomagenesis
@en
The genomic landscape of Walde ...... ed with B-cell lymphomagenesis
@nl
prefLabel
The genomic landscape of Walde ...... ed with B-cell lymphomagenesis
@ast
The genomic landscape of Walde ...... ed with B-cell lymphomagenesis
@en
The genomic landscape of Walde ...... ed with B-cell lymphomagenesis
@nl
P2093
P3181
P1433
P1476
The genomic landscape of Walde ...... ed with B-cell lymphomagenesis
@en
P2093
Christina Tripsas
Christopher J Patterson
Guang Yang
Patricia Sheehy
Robert J Manning
Steven P Treon
Yangsheng Zhou
P304
P3181
P356
10.1182/BLOOD-2013-09-525808
P407
P577
2014-03-13T00:00:00Z